<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01315587</url>
  </required_header>
  <id_info>
    <org_study_id>23456</org_study_id>
    <nct_id>NCT01315587</nct_id>
  </id_info>
  <brief_title>Repetitive Transcranial Magnetic Stimulation and Intermittent Theta Burst (iTBS) in Schizophrenia</brief_title>
  <official_title>A Double-blind Placebo Controlled Trial the Comparison of Effectiveness of Repetitive TMS and iTBS on Negative Symptoms and Cognition in Patients With Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Tehran</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Tehran</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The pilot studies have showed that theta burst stimulation (TBS) can have the more rapid and
      durable effects to the apply traditional rTMS protocols. The aim of this study is to
      investigate the effect of repetitive TMS and theta burst in reduction of negative symptoms
      and remission of cognitive functioning in patients with schizophrenia. In a randomized,
      double blind clinical trials, 30 patients with schizophrenia in Razi psychiatric hospital
      will be assigned to receive repetitive TMS; theta burst, or sham TMS, daily; for 20 sessions.
      The negative symptoms and cognitive functioning will be assessed before the treatment (pre
      test) during the treatment (session 10), and after the treatment (post test).QEEG and LORETA
      apply before and after rTMS in all subjects.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Positive and negative syndrome scale ( PANSS )</measure>
    <time_frame>Change of baseline in negative symptoms at 20 sessions</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Calgary depression for schizophrenia scale (CDSS)</measure>
    <time_frame>3 times (Before treatment, session 10, immediately after treatment)</time_frame>
    <description>The CDSS is administered for measuring of depression before treatment, session 10, immediately after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Schizophrenia quality of life scale (SQLS)</measure>
    <time_frame>3 times (Before treatment, session 10, immediately after treatment)</time_frame>
    <description>The SQLS is administered for apprising of quality of life before treatment, session 10, immediately after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cantab Schizophrenia Battery</measure>
    <time_frame>3 times (Before treatment, session 10, immediately after treatment)</time_frame>
    <description>Cantab Schizophrenia Battery is included six tests, which is measuring for cognitive function. The cognitive function includes reaction time, executive function, Sustained attention, , Episodic memory . These scales:
Reaction time (RTI) Rapid Visual information processing (RVP) Spatial Working Memory (SWM) One Touch Stockings of Cambridge (OTS) Paired Associates Learning (PAL) Intra-Extra Dimensional set- Shift (IED)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QEEG and low resolution brain electromagnetic tomography (LORETA)</measure>
    <time_frame>3 times (Before treatment,session 10, immediately after treatment)</time_frame>
    <description>QEEG and LORETA is applying for assessment brain waves patterns.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Hamilton Depression Rating Scale (HAMD-17)</measure>
    <time_frame>3 times (Before treatment,session 10, immediately after treatment)</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>intermittent theta burst stimulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>repetitive Transcranial Magnetic Stimulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham TMS</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>repetitive Transcranial Magnetic Stimulation (Magstim rapid2 )</intervention_name>
    <description>3 pulses at 50Hz repeated each 200 ms for 2 seconds
80% MT
20 days treatment</description>
    <arm_group_label>intermittent theta burst stimulation</arm_group_label>
    <other_name>TMS</other_name>
    <other_name>rTMS</other_name>
    <other_name>TBS</other_name>
    <other_name>iTBS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>repetitive Transcranial Magnetic Stimulation (Magstim rapid2)</intervention_name>
    <description>LDLPFC 110% MT 15 Hz 20 days</description>
    <arm_group_label>repetitive Transcranial Magnetic Stimulation</arm_group_label>
    <other_name>TMS</other_name>
    <other_name>rTMS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>repetitive Transcranial Magnetic Stimulation(Magstim rapid2)</intervention_name>
    <description>Placebo treatment: Sham coil</description>
    <arm_group_label>Sham TMS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Outpatients male and female with the range of 18-50 years of age

          2. The diagnosis of schizophrenia according to DSM-IV-TR

          3. Completion of consent form

          4. Being under supervision of a psychiatrist,

          5. Being able to adhere to treatment schedule,

          6. Having stable symptoms as defined by not requiring a change in antipsychotic
             medication for at least 4 weeks or at least 2 weeks for psychotropic agents prior to
             entering the Study

        Exclusion Criteria:

          1. The history of rTMS treatment for any reason

          2. Cardiac pacemaker

          3. Drug pumps

          4. Acute heart attack

          5. The risk of seizure with any reasons

          6. The history of epilepsy or seizure in the first relatives

          7. Any metal in head

          8. Brain trauma

          9. Pregnancy

         10. Breastfeeding

         11. Drug dependency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Reza kazemi, PhD</last_name>
    <phone>009802184012128</phone>
    <email>rezakazemi@ut.ac.ir</email>
  </overall_contact>
  <location>
    <facility>
      <name>Atieh Clinical Neuroscience Center (ACNC)</name>
      <address>
        <city>Tehran</city>
        <zip>1969713663</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reza Rostami, MD</last_name>
      <phone>009802184012101</phone>
      <email>rrostami@ut.ac.ir</email>
    </contact>
    <investigator>
      <last_name>Reza Rostami, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Reza Kazemi, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sanaz Khomami, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2011</study_first_submitted>
  <study_first_submitted_qc>March 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2011</study_first_posted>
  <last_update_submitted>August 30, 2015</last_update_submitted>
  <last_update_submitted_qc>August 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Tehran</investigator_affiliation>
    <investigator_full_name>reza kazemi</investigator_full_name>
    <investigator_title>Researcher</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

